title: Effect of basic fibroblast growth factor on left ventricular geometry in rats subjected to coronary occlusion and reperfusion.
abstract: BACKGROUND
  Previous studies have demonstrated myocardial salvage by basic fibroblast growth factor administration following chronic myocardial ischemia or acute myocardial infarction.
  
  
  OBJECTIVE
  To study the effect of bFGF on left ventricular morphometry following coronary occlusion and reperfusion episode in rats.
  
  
  METHODS
  bFGF (0.5 mg) or placebo was continuously administered for a period of one week using an implanted osmotic pump. Animals were sacrificed 6 weeks after surgery and myocardial cross-sections were stained with Massontrichrome and with anti-proliferating cell nuclear antigen antibody.
  
  
  RESULTS
  LV area, LV cavity diameter, LV cavity/wall thickness ratio, and injury size were unchanged compared with control animals. Proliferating endothelial cells were significantly more abundant in injured compared with normal myocardium, but with no differences between animals treated or not treated with bFGF.
  
  
  CONCLUSIONS
  One week of systemic bFGF administration following coronary occlusion and reperfusion had no additional effect on LV geometry or cellular proliferation in rats.
authors.affiliation: Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel. mickeys@post.tau.ac.il
authors.forename: Mickey
authors.initials: M
authors.lastname: Scheinowitz
authors.forename: Arkady-Avi
authors.initials: AA
authors.lastname: Kotlyar
authors.forename: Shachar
authors.initials: S
authors.lastname: Zimand
authors.forename: Ilan
authors.initials: I
authors.lastname: Leibovitz
authors.forename: Nira
authors.initials: N
authors.lastname: Varda-Bloom
authors.forename: Dan
authors.initials: D
authors.lastname: Ohad
authors.forename: Iris
authors.initials: I
authors.lastname: Goldberg
authors.forename: Santiego
authors.initials: S
authors.lastname: Engelberg
authors.forename: Nafthali
authors.initials: N
authors.lastname: Savion
authors.forename: Michael
authors.initials: M
authors.lastname: Eldar
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D003327:Coronary Disease / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology* / Q000627:therapeutic use*; D006352:Heart Ventricles / Q000187:drug effects* / Q000473:pathology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
chemical_list: D043925:Angiogenesis Inducing Agents; D016222:Fibroblast Growth Factor 2